This article discusses the historical relevance of the approval of cannabidiol (CBD) for epilepsy treatment. Unlike its related compound, marijuana's Δ9-tetrahydrocannabinol, CBD does not have any euphorigenic or withdrawal effects at anticonvulsant doses. CBD also has anti-inflammatory properties. Though CBD's anticonvulsant properties were suggested in a few studies in rodent seizure models, social and regulatory pressures kept it from being clinically implemented. However, CBD was approved for the orphan disease Dravet syndrome in 2018 after its efficacy was established in randomized, placebo-controlled trials in children. The article suggests that CBD's approval is a key driver of a new discovery strategy for epilepsy treatment in the 21st century.
This review highlights the potential of using peach by-products, such as peel, stone, and pomace, as sources of bioactive compounds for new functional food products. These by-products make up 10% of the global annual production of peaches. The review includes information on recent peach production, extraction methods for valuable components, and in vivo studies demonstrating anti-inflammatory, anti-obesity, and anti-cerebral ischemia activities. The circular bioeconomy approach encourages the use of these by-products for sustainable food production. The review provides proposals for further studies on food-product design.